Sort   by:  
 Page size 
UnknownAntimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
Not available
S-EPMC5747363 | biostudies-literature
UnknownChloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.
Not available
S-EPMC2954758 | biostudies-literature
UnknownGenome-wide transcriptome profiling reveals functional networks involving the Plasmodium falciparum drug resistance transporters PfCRT and PfMDR1.
Not available
S-EPMC4687325 | biostudies-literature
UnknownInvestigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
Not available
S-EPMC2935017 | biostudies-literature
UnknownAssessing risks of Plasmodium falciparum resistance to select next-generation antimalarials.
Not available
S-EPMC8282644 | biostudies-literature
UnknownA novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants.
Not available
S-EPMC11521309 | biostudies-literature
ProteomicsThermal proteome profiling of MMV897615
The target deconvolution of MMV897615 was evaluated using thermal proteome profiling (TPP), a chemical proteomics approach based on the stabilisation of protein targets upon ligand binding. In these TPP experiments we used a whole-cell strategy, exposing cells rather than lysates to the drug
ORGANISM(S): Plasmodium falciparum (isolate 3D7) 
2023-03-09 | PXD034937 | Pride
Acyl-coa synthetases Drug target Thermal proteome profiling Plasmodium falciparum 
ProteomicsMixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets
Malaria, caused by Plasmodium falciparum, remains a significant health burden. The barrier for developing anti-malarial drugs is the ability of the parasite to rapidly generate resistance. We previously demonstrated that Salinipostin A (SalA), a natural product, potently kills parasites by inhibitin...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum (isolate 3D7) 
2024-07-15 | PXD051499 | Pride
Plasmodium Lipid metabolism Serine hydrolases Activity-based probes 
UnknownSafety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
Not available
S-EPMC8612936 | biostudies-literature
UnknownSupergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate.
Not available
S-EPMC4167585 | biostudies-literature
Sort   by:  
 Page size